Section Arrow
ANAB.NASDAQ
- AnaptysBio
Quotes are at least 15-min delayed:2025/11/04 04:20 EST
Pre Market
Last
 --
-- (--)
Bid
33
Ask
39.85
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 36.04
-0.54 (-1.48%)
Day High 
37.12 
Prev. Close
36.58 
1-M High
38.385 
Volume 
314.07K 
Bid
33
Ask
39.85
Day Low
35.535 
Open
36.21 
1-M Low
29.48 
Market Cap 
1.02B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 35.36 
20-SMA 33.82 
50-SMA 27.14 
52-W High 38.385 
52-W Low 12.21 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.39/-4.83
Enterprise Value
1.04B
Balance Sheet
Book Value Per Share
-1.60
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
91.28M
Operating Revenue Per Share
0.53
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PHIOPhio Pharmaceuticals Corp1.86-0.19-9.27%0.01PE
Pre Market 1.67 -0.19 -10.22%
CRBUCaribou Biosciences2.43+0.01+0.41%-- 
Pre Market 2.37 -0.06 -2.47%
IOVAIovance Biotherapeutics1.95-0.02-1.02%-- 
Pre Market 1.975 +0.025 +1.28%
RXRXRecursion Pharmaceuticals5.44-0.08-1.45%-- 
Pre Market 5.28 -0.16 -2.94%
THARTharimmune Inc.3.2+0.25+8.47%0.03PE
Pre Market 3.14 -0.06 -1.88%
Quotes are at least 15-min delayed:2025/11/04 04:20 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) anda Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.